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Phe Frequency and Incremental Cost of Major
omplications Among Medicare Beneficiaries
eceiving Implantable Cardioverter-Defibrillators
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hillip P. Brown, MD,‡ Edmund R. Becker, PHD,§ Steven D. Culler, PHD,§ April W. Simon, MSN
oston, Massachusetts; Detroit, Michigan; Nashville, Tennessee; and Atlanta, Georgia
OBJECTIVES We aimed to quantify the frequency and nature of early complications after implantable
cardioverter-defibrillator (ICD) implantation in general practice, and estimate the incremen-
tal costs of those complications to the health care system.
BACKGROUND Cardioverter-defibrillator implantation rates are rising quickly. Little has been published
regarding the outcomes and costs of these procedures in unselected populations.
METHODS Using Medicare Provider Analysis and Review (MedPAR) files, we identified 30,984
admissions containing procedure codes for new ICD or cardiac resynchronization therapy
defibrillator implantation in fiscal year 2003. The frequencies of eight complicating diagnoses
during these admissions were determined. Length of stay (LOS) and total hospital costs,
derived using whole-hospital cost to charge ratios, were calculated for each admission. The
incremental effects of any and each complication on LOS and hospital cost were estimated in
multivariable models, adjusting for demographic factors and comorbid conditions.
RESULTS The mean cost for all admissions was $42,184 (median $37,902) with mean LOS of 4.7 days
(median 2.0 days). One or more complications were coded in 10.8% of admissions, most
commonly “mechanical complication of the ICD” and hemorrhage/hematoma. The occur-
rence of any complication increased adjusted LOS by 3.4 days and costs by $7,251. Each of
the individual complications was associated with highly significant increases in both LOS
(1 to 10 days) and hospital cost ($5,000 to $20,000).
CONCLUSIONS In fiscal 2003, 10.8% of Medicare patients undergoing cardioverter-defibrillator implantation
experienced one or more early complications, associated with significant increases in LOS and
costs. Efforts to reduce these complications could have significant clinical and financial
benefits. (J Am Coll Cardiol 2006;47:2493–7) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.049Cardiology Foundation
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rased on the findings of recent primary prevention trials
1–3), the utilization of implantable cardioverter-defibrillators
ICDs) in the U.S. is expected to increase at least two- to
hree-fold over the next several years (4). The financial
mplications of expanded cardioverter-defibrillator implan-
ation have generated concern among large payers and some
embers of the clinical community, who feel that patient
election criteria could be better refined (4–8).
Little has been published concerning implant-related
omplications or costs based on large, unselected patient
opulations of ICD recipients. Analysis and reporting of
CD procedural complications will be of interest as non-
lectrophysiologists begin to implant more devices (9), and
s an expressed goal of the newly created Medicare ICD
egistry (10).
The objectives of the present investigation were to estimate
he cost of cardioverter-defibrillator implantation among
edicare beneficiaries in routine clinical practice, and to
xamine the frequency of and cost associated with major
omplications of cardioverter-defibrillator implantation.
From the *Beth Israel Deaconess Medical Center, Boston, Massachusetts; †Henry
ord Hospital, Detroit, Michigan; ‡Centennial Medical Center, Nashville, Tennes-
ee; §Emory University, Atlanta, Georgia; and Cardiac Data Solutions, Atlanta,
eorgia.s
Manuscript received October 18, 2005; revised manuscript received February 8,
006, accepted February 14, 2006.ETHODS
nalytic cohort. We obtained data for the current analysis
rom the Medicare Provider Analysis and Review (MedPAR)
le for fiscal year 2003. The MedPAR files contain admin-
strative data for all claims submitted to the Centers for
edicare and Medicaid Services (CMS) by U.S. short-stay
ospitals for services provided to Medicare beneficiaries. For
ach hospitalization, the MedPAR files contain information
n basic patient demographics (age, gender, race); admis-
ion and discharge dates; principal discharge diagnosis,
oded according to the International Classification of
iseases-9th Revision-Clinical Modification (ICD-9-
M); up to eight secondary ICD-9-CM diagnosis codes;
p to six ICD-9-CM procedural codes; and discharge
tatus. Fiscal data for each admission include aggregrate and
ost-center–specific hospital charges, total reimbursement,
nd the hospital’s Medicare provider number. The validity
f identifying comorbid conditions from such administra-
ive data has been previously established (11).
The study population consisted of Medicare beneficiaries
ho underwent cardioverter-defibrillator implantation be-
ween October 1, 2002, and September 30, 2003, as
dentified by ICD-9-CM codes 37.94 (implantation or
eplacement of automatic cardioverter-defibrillator, total
ystem) and 00.51 (implantation of a cardiac resynchroni-
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ICD Complications: Frequency and Costs June 20, 2006:2493–7ation defibrillator, total system). These procedure codes are
eant to specify total system implantation. Therefore,
enerator replacements, lead replacement/revision, and up-
rade of prior devices generally should not have been
ncluded. Of the initial 53,936 cases identified using the
bove procedure codes, 22,952 patients who underwent one
r more additional major cardiovascular procedures (cardiac
atheterization, cardiac surgery, percutaneous coronary in-
ervention, pacemaker or catheter ablation; Appendix Table
) during the same admission were excluded from analysis in
rder to avoid confounding causes for in-hospital compli-
ations and costs of multiple procedures. The remaining
0,984 cases comprised the primary analytic cohort.
nalytic methods. Complications of interest for this anal-
sis included: in-hospital death; implant-related infection;
ematoma or hemorrhage; mechanical complication of the
CD (e.g., lead dislodgement); pneumothorax; cardiac per-
oration with pericardial effusion or tamponade; and acute
enal failure with new-onset hemodialysis. These complica-
ions were selected based on review of pertinent clinical
iterature (1–3,12–16) and corresponding ICD-9-CM
odes, in consultation with a hospital coder. The ICD-
-CM codes used to identify each of these complications are
isted in the Appendix.
The outcome variables of interest, beyond the complica-
ions themselves, were length of stay (LOS) and total cost
or the index hospitalizations. Length of stay was defined as
he number of days from admission to discharge. Hospital cost
as estimated by multiplying total charges submitted to CMS
y the admitting hospital’s overall cost-to-charge ratio, found
n the 2003 or most recently settled Medicare Cost Report
17,18). This method of cost calculation thus does not include
hysician fees for services during the hospitalization.
tatistical methods. Data are presented as frequencies for
iscrete variables and mean values  SD for continuous
ariables. The reporting of mean values is justified based on
he large sample sizes, and because mean values best reflect
xpected expenditures from a payer perspective. Univariate
etween-group comparisons were performed using Fisher
xact tests for binary variables, chi-square tests for categor-
cal variables, and two-sample t tests for continuous vari-
bles. All reported p values are two-tailed. A p value 0.05
Abbreviations and Acronyms
CMS  Centers for Medicare and
Medicaid Services
CRT-D  cardiac resynchronization therapy-
defibrillator
ICD  implantable cardioverter-defibrillator
ICD-9-CM  International Classification of Diseases-
9th revision-Clinical Modification
LOS  length of stay
MEDPAR  Medicare Provider Analysis and Reviewas considered to be statistically significant. cMultivariable linear regression models were constructed
n the outcomes of total hospital cost and LOS, in order to
stimate the incremental impact of individual complications
n those outcomes, while adjusting for differences in base-
ine characteristics between subjects with and without com-
lications. These models are adjusted for age, gender, race,
nd 32 comorbid conditions listed among the discharge
iagnoses. The incremental resources associated with a
articular complication were estimated as the regression
oefficient for the dichotomous variable set to one if the
atient experienced the complication and set to zero for all
ther patients. Although log-linear relationships were ex-
lored, we report only the results of the linear models, as the
nterpretation is more straightforward, and the results did
ot differ significantly between the two approaches. Sepa-
ate models were also constructed with a term for any
omplication (versus none), adjusted for the same demo-
raphic and clinical variables, in order to estimate the
ncremental cost and LOS of having a complication of any
ind. All analyses were performed using SAS version 8.2
tatistical software (SAS Institute, Cary, North Carolina).
ESULTS
n fiscal 2003, after excluding 21,952 patients who under-
ent additional invasive cardiovascular procedures during
he same hospital admission, we identified 30,984 Medicare
atients who underwent ICD (74.6%) or cardiac resynchro-
ization therapy-defibrillator (CRT-D) (25.4%) implantations
t 1,122 hospitals (median hospital implant volume  15).
he mean hospital cost for these admissions was $42,184 
23,199 (median $37,902), and mean LOS was 4.7 6.0 days
median 2.0 days).Mean unadjusted hospital costs were $4,768
igher for admissions involving CRT-D implantation, com-
ared with standard cardioverter-defibrillator implantation.
his value was minimally changed after adjustment for patient
haracteristics, complications, and LOS.
able 1. Frequency of Specific Complications During ICD
ospitalizations for the Entire Study Population, Stratified
y Type of Implant
Complication
ICD
(n  23,110)
CRT-D
(n  7,874) p Value*
ny complication† 11.0% 10.5% NS
echanical complication
of ICD system
4.8% 3.8% 0.001
With lead or pocket revision 1.2% 1.8% 0.001
ematoma/hemorrhage 2.5% 3.4% 0.0001
nfection associated
with implant
1.4% 0.7% 0.0001
neumothorax 1.0% 1.2% NS
eath 0.9% 1.1% 0.07
ther cardiac complications 0.8% 0.7% NS
ericardial effusion/tamponade 0.3% 0.3% NS
cute renal failure with
new hemodialysis
0.3% 0.3% NS
All p values are from Fisher exact tests; †complications are not mutually exclusive.
CRT-D  cardiac resynchronization therapy-defibrillator; ICD  implantable
ardioverter-defibrillator.
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June 20, 2006:2493–7 ICD Complications: Frequency and CostsTable 1 and Figure 1 summarize the frequency and nature
f the complicating diagnoses documented in the MedPAR
les. Overall, 10.8% of patients suffered one or more
omplications during the hospital stay in which their
ardioverter-defibrillator was implanted. Most patients with
omplications had only one. The overall complication rate
as similar whether an ICD or CRT-D device was im-
lanted, although slight differences for a few individual
omplications were observed (Table 1).
Death occurred before hospital discharge in 0.9% of
ases. Among patients who died, 33% had one or more
dditional complications as listed in Table 1 during the
ame hospitalization, most commonly “other cardiac com-
igure 1. Frequency distribution of the number of complications for the
ntire study population.
able 2. Baseline Characteristics of ICD Recipients With
nd Without Acute Complications
Complication
Group
(n  3,358)
No
Complication
Group
(n  27,626) p Value
emographics
Age 65–74 yrs 39.3% 40.9% 0.07*
75–84 yrs 39.9% 39.5%
84 yrs 5.8% 5.8%
Female gender 23.3% 21.0% 0.002
Non-Caucasian 13.5% 11.7% 0.004
ardiac conditions
CHF 59.6% 59.8% NS
AMI (primary diagnosis) 5.0% 3.6% 0.0001
Cardiogenic shock 1.5% 0.3% 0.0001
Ventricular tachycardia 57.0% 65.9% 0.0001
Ventricular fibrillation 8.6% 6.1% 0.0001
Cardiac arrest 3.2% 1.3% 0.0001
omorbid conditions
Diabetes mellitus 21.1% 27.5% 0.0001
Chronic renal failure 2.1% 1.5% 0.02
COPD 21.7% 18.9% 0.0001
Cerebrovascular disease 14.5% 14.2% NS
evice type
CRT-D 24.6% 25.5% NS
p value from chi-square test. All other p values in this table are from Fisher exact test.
AMI  acute myocardial infarction; CHF  congestive heart failure; COPD hronic obstructive pulmonary disease; CRT-D  cardiac resychronization therapy-
efibrillator; ICD  implantable cardioverter-defibrillator.
l
clication” (8.4%), pneumothorax (6.3%), and mechanical
omplication of the ICD (5.6%).
The baseline characteristics of patients with and without
omplications during the same hospital admission as their
CD procedure are shown in Table 2. Patients who expe-
ienced complications, compared with those without, were
lightly more often women and non-white, and more likely
o have acute myocardial infarction, ventricular fibrillation,
ardiac arrest, and chronic pulmonary or renal disease.
atients not experiencing an acute complication were more
ikely to have a diagnosis code for ventricular tachycardia
nd have a history of diabetes mellitus.
Patients with any complication, compared with those
ith none, generated $8,769 in increased hospital costs and
.3 days in increased LOS in unadjusted analyses (Fig. 2).
fter adjustment for baseline patient characteristics, the
ifference in mean costs decreased to $7,251/patient and in
OS to 3.4 days.
Table 3 displays the adjusted incremental cost for each of
he common individual complications observed, as well as
he adjusted increase in hospital LOS. The listed compli-
ations each increased average hospital costs by between
5,000 (for pneumothorax) and $20,000 (for death), with
igure 2. Observed and adjusted average hospital cost for patients with
solid bars) and without complications (open bars).
able 3. Adjusted Incremental Hospital Resource Utilization
ssociated With Treating Patients Experiencing the
omplication of Interest
Complication
Incremental
Cost*
Incremental
LOS (Days)*
eath $20,547 8.3
nfection associated with implant $18,477 9.6
cute renal failure with new hemodialysis $16,684 7.5
ericardial effusion/tamponade $8,249 1.9
ematoma/hemorrhage $6,995 3.1
ther cardiac complications $6,136 1.6
echanical complication with lead or
pocket revision†
$5,436 1.3
neumothorax $5,301 2.9
All estimated incremental costs and length of stay (LOS) values are significantly
ifferent from zero (p  0.001); †mechanical complication without code for
ead/pocket revision associated with statistically non-significant change in-hospital
osts.
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ICD Complications: Frequency and Costs June 20, 2006:2493–7ssociated increases in LOS from 1 to 10 days. The
iagnostic code for mechanical complications of an ICD
as associated with significantly increased cost and LOS
nly when a code for lead or pocket revision was also
resent. When a term for LOS was added to the model on
osts, four of the eight complications (death, tamponade,
echanical complication with lead/pocket revision, and
other cardiac”) were shown to increase costs independent of
OS; in other words, these complications increased both
he intensity and duration of care.
Beyond the complications listed in the tables, an addi-
ional 1,492 patients (4.8%) were found to have diagnosis/
rocedure codes for acute renal failure or new-onset hemo-
ialysis during the admissions in which their cardioverter-
efibrillators were implanted. Because renal failure is not an
xpected complication of cardioverter-defibrillator implan-
ation, we estimated incremental costs and LOS only for the
mall group coded for both acute renal failure and new
emodialysis.
ISCUSSION
n this analysis of over 30,000 Medicare beneficiaries under-
oing new cardioverter-defibrillator implantation in fiscal year
003, we found that 10.8% experienced one or more compli-
ations before hospital discharge. On average, the occurrence
f any complication increased adjusted hospital costs by
$7,250, an increase of nearly 20% over an uncomplicated
dmission. If 100,000 cardioverter-defibrillators were im-
lanted this year with similar results, the incremental cost of
hese complications would exceed $78 million.
Reported complication rates from cardioverter-defibrillator
mplantation may depend on the type of device implanted, and
ay also vary with definitions and the time frame of patient
bservation (19). Multicenter studies of early-generation
ransvenous ICDs reported surgical complication rates of
2% or higher (14,15). Common issues were lead dislodge-
ent and wound or pocket problems. More recent ICD
rials have reported lower acute complication rates, ranging
rom 1% to 8% (1–3,13), with the higher estimate including
nappropriate shocks before hospital discharge (13). These
ecent trial data are concordant with survey data and
ingle-center reports that estimate complication rates after
acemaker implantation of 4% to 7% (12,16).
Although direct comparisons are difficult, the overall
requency of complications in our study appears to be higher
han that reported in recent clinical trials. Medicare patients
ho receive ICDs may, on average, be older and may have
higher prevalence of comorbid disease than typical clinical
rial patients. A recent study also documented a relationship
etween low implant volumes and increased complication
ates and found that the majority of implanting physicians
n the U.S. had relatively low volumes of cases submitted to
edicare (20). Thus, higher complication rates may, to
ome extent, be expected in the Medicare population based
n both patient and physician factors. rWe did not find a difference in overall complication rates
etween ICD and CRT-D implants. In contrast, recent
rials of CRT-D devices have reported higher (10% to 28%)
requencies of acute complications than those observed
n recent ICD trials involving standard single and dual-
hamber devices (21,22). This could be because only very
killed operators were implanting CRT devices in 2003, or
ecause some CRT-D complications, such as lead dislodge-
ent, may occur after the initial hospital discharge and may
herefore have been underestimated by our methods.
The CMS has established a national ICD registry, in part
o evaluate whether the costs and outcomes of cardioverter-
efibrillator implantation differ in general practice com-
ared with clinical trials (23). The present data support the
ationale for this registry, and can serve as both benchmarks
e.g., for new implanting hospitals or physicians) and as
argets for quality improvement. Previous studies indicate
hat several common complications of cardioverter-
efibrillator implantation may be preventable (19,24–26).
ur data suggest that dedicated quality improvement efforts
ould substantially enhance patient safety, and that, in light
f their economic impact, successful initiatives to reduce
rocedural complications could pay for themselves.
Our data may also have implications for cost-effectiveness
odeling. Trial-based analyses are able to directly incorporate
bserved complication costs in their calculations, but compli-
ation rates seen in the clinical trial setting are probably not
epresentative of general practice. Model-based analyses, on
he other hand, have either incorporated limited data on
rocedural complications (27) or have used old data for
odel inputs (28). In both scenarios, the true costs of
rocedural complications may have been underestimated.
Economic analyses of clinical trials also tend to focus on
ardioverter-defibrillator implantation as an isolated proce-
ure. This perspective would appear to grossly underes-
imate the true costs of providing care for the kind of
atients in whom cardioverter-defibrillators are currently
eing implanted. Our data demonstrate that cardioverter-
efibrillator implantation is very often performed as one
f multiple invasive cardiac procedures during a single
ospital admission. Even though we excluded patients
ith additional cardiac procedures from our analysis, the
verage hospital costs for our study cohort ($42,000, not
ncluding physician fees) were much higher than those used
n contemporary ICD cost-effectiveness studies. The costs
or hospitalizations in which cardioverter-defibrillators are
mplanted in addition to other cardiac procedures stand to
e substantially higher.
Several important limitations of our study must be
cknowledged. Our analyses rely on administrative data,
hich has well-recognized strengths and weaknesses. Both
omplications and comorbid illnesses could have been un-
erreported. We made reasonable attempts to avoid con-
ounding explanations for the complications that we de-
ned, but cannot be certain that all of the complications we
eport were related to the implant procedures. Cardioverter-
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June 20, 2006:2493–7 ICD Complications: Frequency and Costsefibrillator implants performed on an outpatient basis were
ot included. Potentially important clinical details were also
navailable; for example, the diagnostic code for “mechan-
cal complications” (996.0), is non-specific, making clinical
nterpretation of its frequency difficult.
Our analysis was also limited to the hospitalizations
uring which cardioverter-defibrillators were implanted.
ur estimates therefore represent a lower bound on the total
requency of cardioverter-defibrillator implant complica-
ions and their cost, which would also include physician fees
or inpatient care, outpatient care, and re-hospitalizations.
ome implant-related complications—in one pacemaker
rial, as many as 30%—do not occur or are not recognized
ntil after the initial hospitalization (20,29,30).
Finally, we estimated costs on the basis of hospital
harges and whole-hospital cost to charge ratios. This
ethod may be inaccurate for high-expense items like
CDs. Although hospital costs can be calculated more
recisely using alternative methods, such methods are not
ractical to apply to a large national sample of hospitals.
eprint requests and correspondence: Dr. Matthew R. Reyn-
lds, Division of Cardiology, Baker 4, Beth Israel Deaconess
edical Center, 185 Pilgrim Road, Boston, Massachusetts 02215.
-mail: mreynold@bidmc.harvard.edu.
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PPENDIX
or supplementary tables 1 and 2, please see the online
ersion of this article.
